Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Acquires $24,840.24 in Stock

Posted by Mark Dietrich on May 21st, 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. acquired 996 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $24.94 per share, for a total transaction of $24,840.24. Following the transaction, the insider owned 6,376,968 shares of the company’s stock, valued at approximately $159,041,581.92. The trade was a 0.02% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Tuesday, May 19th, Ra Capital Management, L.P. acquired 3,802 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.97 per share, for a total transaction of $94,935.94.
On Tuesday, May 12th, Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.90 per share, for a total transaction of $159,036.30.
On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.81 per share, for a total transaction of $989,149.89.
On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.98 per share, for a total transaction of $37,045.34.
On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.46 per share, for a total transaction of $242,300.76.
On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Price Performance

COAG stock traded down $0.17 during midday trading on Thursday, hitting $26.30. The company’s stock had a trading volume of 193,388 shares, compared to its average volume of 251,804. Hemab Therapeutics Holdings, Inc. has a 1 year low of $23.00 and a 1 year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last posted its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th.

Get Our Latest Stock Report on COAG

About Hemab Therapeutics

(Get Free Report)

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.